Status:
COMPLETED
Markers for Breast Cancer
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Breast Cancer
Eligibility:
FEMALE
15+ years
Brief Summary
This study will analyze blood samples to identify substances that are associated with the development of breast cancer. It will determine if: * Women who are diagnosed with a benign breast condition ...
Detailed Description
Prevention and treatment of intraepithelial neoplasia and benign pre-malignant conditions has become an important focus of the NCI's 2015 goal of eliminating suffering and death due to cancer, althoug...
Eligibility Criteria
Inclusion
- INCLUSION/EXCLUSION CRITERIA:
- Potentially eligible premenopausal women include 2636 who did not have a previous or concurrent (within 60 days) diagnosis of breast cancer at the time of initial benign breast biopsy (study entry) and who have at least 4 mls of serum stored in the Frederick biorepository.
- Of those 2636, four women have a code indicating "refused study" in the "follow-up" variable, and despite evidence of their consent to the original study, will be omitted from all future use of study data or specimens.
- Participants also will be required to be Caucasian or African American (2599 or 98.6%), and to have a pathology report successfully retrieved from a participating hospital for review.
- All sample sizes subsequently cited in the text take these inclusion criteria into account, and those cited for objective 2 also incorporate adjustment for loss to follow-up.
Exclusion
Key Trial Info
Start Date :
December 1 2004
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
2632 Patients enrolled
Trial Details
Trial ID
NCT00339248
Start Date
December 1 2004
Last Update
March 13 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NCI Frederick Cancer Research Center
Frederick, Maryland, United States, 21702-1201